The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Alternative cellular therapies for patients with CLL
Peter Hillmen, MBChB, FRCP, FRCPath, PhD, University of Leeds, Leeds, UK, shares some insights into cellular therapy for chronic lymphocytic leukemia (CLL), drawing focus to patients who have not responded to either Bruton’s tyrosine kinase (BTK) inhibitors or BCL2 inhibitors. Dr Hillmen mentions the challenge associated with getting CAR-T therapy for these patients, as well as the benefit of these emerging treatment options, including lisocabtagene maraleucel, ibrutinib, and allogeneic transplant. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
